MedTrace Logo

Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia

NCT01164059 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2015-06-22

No results posted yet for this study

Summary

This study is designed to compare the efficacy and drug tolerability of two strategies for the treatment of schizophrenia. The two strategies consist of utilizing, on the one hand, a conventional antipsychotic like haloperidol or flupentixol and, on the other hand, a newer antipsychotic compound like olanzapine, quetiapine or aripiprazole in patients with schizophrenia.

Conditions

Interventions

DRUG

Olanzapine

Olanzapine 10, 15, or 20 mg / day

DRUG

Flupentixol

Flupentixol 6, 9, or 12 mg / day

DRUG

Quetiapine

Quetiapine 400, 600, or 800 mg / day

DRUG

Aripiprazole

Aripiprazole 10, 15, or 20 mg / day

DRUG

Haloperidol

Haloperidol 3, 4.5, or 6 mg / day

Sponsors & Collaborators

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV

  • University of Bremen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2013-08-31
Completion
2014-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01164059 on ClinicalTrials.gov